Chronic Myeloid Leukemia Treatment Market 2021 Global Analysis, Size, Trends, Share, Growth, Competitive Landscape, Key Players, Regional And Industry Forecast To 2026
SEATTLE, April 01, 2021, (PHARMIWEB) — Chronic myeloid leukemia (CML) also known as chronic myelogenous leukemia, is a blood-cell cancer that begins in the blood-forming cells of the bone marrow. Myeloid cells are type of immature cells that are capable of making white blood cells and when these cells continue to grow in an abnormal condition, it turns into a chronic myeloid leukemia condition. This cancer majorly causes fatigue, fever, easy bleeding, infection, bone pain, anemia, and swollen spleen among the patients who are middle-aged people or older, though it can occur in children also. CML is a slowly growing leukemia, however, it can also change into a fast-growing acute leukemia, which is difficult to treat. Continuous support from the regulatory bodies by approving the pipeline drugs for CML is expected to propel growth of the market over the forecast period. For instance, in February 2014, Teva Pharmaceutical Industries Ltd.’s drug, SYNRIBO (omacetaxine mepesuccinate) for adult patients with chronic phase or accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors (TKIs) got the U.S. FDA approval.
To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/1726
Chronic Myeloid Leukemia Treatment Market Drivers
Increasing number of researches that are carried out to identify the causes of CML cancer is expected to boost growth of the chronic myeloid leukemia treatment market over the forecast period. Targeted drug known as tyrosine-kinase inhibitors (TKIs) are effective in providing long-term survival rates. Furthermore, the Food and Drug Administration (FDA) approved dasatinib (Sprycel) for the treatment of chronic myeloid leukemia in pediatrics in 2017. Researchers are also focusing on polypharmacology approach to develop drugs that can act on multiple targets. This is leading to the drug discovery opportunities that are beyond the concept of ‘one drug, one target’.
Chronic myeloid leukemia is more aggressive in younger patients, the approval of drugs can help in effective treatment. Moreover, with the development of imatinib and second generation TKIs, dasatinib and nilotinib, small molecule drugs have become the mainstay for the first-line CML management. However, high cost of the drugs for treatment of this disease is a major restraint that is expected to hamper growth of the market. For instance, TKIs drugs are very expensive, therefore generic drugs are introduced in various countries. Increasing prevalence of this cancer in various regions is expected to drive growth of the market over the forecast period. For instance, according to an article published in UBM Medica LLC, CML accounts for around 15% of the total leukemia cases in adults. Around 8,220 new cases of CML were diagnosed in 2016, with an estimated 1,070 deaths. The age-adjusted incidence is 1.6 per 100,000 population.
Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations
Buy-Now this Research Report @ https://bit.ly/3rFDT2L
Chronic Myeloid Leukemia Treatment Market – Regional Analysis
On the basis of region, the global chronic myeloid leukemia market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to gain significant traction in the chronic myeloid leukemia treatment market, followed by Europe, owing to increasing prevalence of chronic myelogenous leukemia in developed economies due to genetic factors. For instance, according to the American Cancer Society, around 8,430 new cases of CML were observed (4,980 in men and 3,450 in women) in 2018, and around 1,090 people were reported to die due to CML (620 men and 470 women). However, improving healthcare infrastructure in emerging economies such as China and India are contributing towards the growth of chronic myeloid leukemia treatment market in the Asia Pacific region.
Chronic Myeloid Leukemia Treatment Market – Competitive Landscape
Tough competition between major players to retain their market share in CML market may provide opportunities to come up with altered solutions in drug development and new strategies to embrace the mindset of the end users. Since 2015, majority of the drugs offered by major players for this condition were approved. There are commercialized products, which include Bristol Meyer Squibb’s Sprycel (approved in December, 2017), Novartis’s Gleevec and Tasigna (approved in March, 2018), Takeda Pharmaceuticals’ Iclusig (approved in 2018), and Pfizer’s Bosulif (approved in December, 2017).
The market players operating in the chronic myeloid leukemia treatment market include Teva Pharmaceuticals Industries Ltd., Hoffman-La Roche Ltd., Novartis AG, Bristol-Myers Squibb, Pfizer, Inc Hospira, Inc., Prism Pharmaceuticals, Incyte Corporation, Bio-Path Holdings, Stragen Pharma SA, and Otsuka Pharmaceutical Co., Ltd among others.
Note: *The Download PDF brochure only consist of Table of Content, Research Framework, and Research Methodology.
Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/1726
Chronic Myeloid Leukemia Treatment Market Taxonomy
By Drug Type
- Bosulif (Bosutinib)
- Gleevec (Imatinib)
- Iclusig (Ponatinib)
- Sprycel (Dasatinib)
- Tasigna (Nilotinib)
- Synribo (Omacetaxine Mepesuccinate)
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- North America
- Latin America
- Asia Pacific
- Middle East
To get detailed table of content (ToC), please click – https://www.coherentmarketinsights.com/ongoing-insight/toc/1726
Table of Content
Global Chronic Myeloid Leukemia Treatment Market Research Report
Section 1: Global Chronic Myeloid Leukemia Treatment Industry Overview
Section 2: Global Economic Impact on Chronic Myeloid Leukemia Treatment Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Chronic Myeloid Leukemia Treatment Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Chronic Myeloid Leukemia Treatment Market Forecast
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire